Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Imatinib mesylate
Drug ID BADD_D01137
Description Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.
Indications and Usage For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).
Marketing Status Prescription; Discontinued
ATC Code L01EA01
DrugBank ID DB00619
KEGG ID D01441
MeSH ID D000068877
PubChem ID 123596
TTD Drug ID D0AZ3C
NDC Product Code 55111-939; 64679-793; 72606-557; 63629-2067; 11722-052; 0904-6621; 60505-2901; 68382-244; 68382-245; 68001-490; 16714-705; 72485-203; 51991-376; 64679-794; 72485-202; 62068-309; 67877-634; 54893-0066; 63629-2068; 81955-0002; 72606-556; 62756-875; 68001-491; 47335-475; 70771-1394; 60505-2900; 0078-0401; 0904-6901; 60687-192; 42385-720; 0054-0249; 51991-377; 47335-472; 65344-0020; 0054-0248; 16714-704; 50268-426; 59651-240; 59651-241; 73309-059; 67877-633; 0093-7629; 42385-316; 0078-0649; 71052-670; 60687-203; 59923-723; 54893-0005; 59651-610; 0093-7630; 66499-0073; 70771-1395; 50268-427; 72969-033; 59923-724
Synonyms Imatinib Mesylate | Mesylate, Imatinib | Imatinib Methanesulfonate | Methanesulfonate, Imatinib | STI571 | STI-571 | STI 571 | Gleevec | Glivec | ST 1571 | ST1571 | CGP 57148 | CGP57148B | CGP-57148 | CGP57148 | Imatinib | Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
Chemical Information
Molecular Formula C30H35N7O4S
CAS Registry Number 220127-57-1
SMILES CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)( =O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Chronic myeloid leukaemiaLeptinP41159T79485Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute generalised exanthematous pustulosis23.03.10.002; 12.03.01.005--Not Available
Onychoclasis23.02.05.005--Not Available
Brain oedema17.07.02.003; 12.01.10.010--
Tumour haemorrhage24.07.01.028; 16.32.03.008--
Scleral haemorrhage24.07.05.009; 06.07.01.002--Not Available
Contusion12.01.06.001; 24.07.06.001; 23.03.11.002; 15.03.01.008--
Eye oedema06.08.03.013--Not Available
Thoracic operation25.13.05.001--Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Growth retardation15.03.01.006--
Tumour necrosis16.32.03.009; 24.04.02.013--Not Available
Transaminases increased13.03.01.015--Not Available
Haemorrhage24.07.01.002--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.012--Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.006--Not Available
Skin toxicity12.03.01.020; 23.03.03.032--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Haemorrhagic ovarian cyst24.07.03.014; 21.11.01.007; 16.04.03.003--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Embolism24.01.01.009--
Mediastinal disorder22.09.03.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Lichenoid keratosis23.01.01.004--Not Available
Exfoliative rash23.03.07.006--Not Available
Bone marrow failure01.03.03.005--
Pharyngeal inflammation22.04.05.008--
Acute kidney injury20.01.03.016--
Central nervous system haemorrhage17.08.01.035; 24.07.04.016--Not Available
The 9th Page    First    Pre   9    Total 9 Pages